According to the Company, the decision to discontinue the Repatha Pushtronex System was not due to the product’s quality, efficacy or safety. The Repatha Pushtronex System will be discontinued ...

Repatha pushtronex The Pushtronex system is an on-body infusor with a prefilled cartridge intended for once-monthly administration. Amgen announced that the Food and Drug Administration (FDA ...

BETHESDA, MD — The US Food and Drug Administration (FDA) has approved the evolocumab (Repatha, Amgen) Pushtronex system, the first once-monthly delivery option for a proprotein convertase ...

The Repatha Pushtronex system, an on-body infusor with a prefilled cartridge, is a hands-free device intended to provide 420 mg in a single dose. Approval makes Repatha the first and only PCSK9 ...

Amgen said the FDA has approved its Repatha (evolocumab) Pushtronex system, the first hands-free, once-monthly delivery option for a PCSK9 inhibitor. Evolocumab is indicated as an adjunct to ...

Amgen (NASDAQ: AMGN) revealed that the Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system, a fresh, monthly single-dose administration option. According to ...

Biotech giant Amgen (NASDAQ: AMGN) announced yesterday that the FDA has approved the Repatha Pushtronex system. This new system is a pre-filled, on-body medical device that allows for monthly ...

The monthly injection (Repatha Pushtronex system, Amgen) consists of an on-body infusor with a prefilled cartridge of evolocumab (Repatha, Amgen) 420 mg. The single-use device, based on the ...

The FINANCIAL — Amgen on July 11 announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system (on-body infusor with prefilled cartridge), a ...

The FDA approval of the Pushtronex system offers another delivery option to patients who need the additional LDL cholesterol lowering that Repatha can provide. The device was created in ...

The Repatha Pushtronex system, an on-body infusor with a prefilled cartridge, is a hands-free device intended to provide 420 mg in a single dose. Approval makes Repatha the first and only PCSK9 ...